Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog
click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.

Alan Franciscus
Editor-in-Chief
HCV Advocate
HBV Advocate

Sunday, April 22, 2012

Gilead's Hepatitis C Drug Poised To Reach The Market As One Of The First 'All Oral' Combinations

The 100% cure rates from Gilead Sciences' (GILD) and Bristol-Myers Squibb's (BMY) all-oral combination might have taken centre stage day one at the EASL liver conference, but data from other studies of GS-7977 to emerge make equally comforting reading for the drug's proud new owner.

Stronger than expected results emerged from both the Electron and Quantum studies, making it almost certain that the potent nucleotide analogue will form the backbone of the first all-oral hepatitis C therapy to reach the market. Gilead shares soared 14% to $53.31 in early trade.

Read more....

No comments:

Post a Comment